Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTX-001
- Development stage
- Preclinical
- Lead developer
- Venn Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
VTX-001 is a preclinical-stage bispecific antibody developed by Venn Therapeutics for the treatment of neoplasms. It is engineered to simultaneously target and neutralize the TGF-β1 and TGF-β3 isoforms of the Transforming Growth Factor-beta (TGF-β) superfamily. TGF-β signaling in the tumor microenvironment is a key driver of immune suppression, epithelial-mesenchymal transition (EMT), and fibrosis. By blocking these specific isoforms, VTX-001 is intended to alleviate immunosuppression and enhance the efficacy of other cancer therapies, such as checkpoint inhibitors, while potentially avoiding the toxicities associated with pan-TGF-β inhibition.
02
Targets
Beyond the preview
Go deeper on VTX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTX-001.